Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy
Stephen J. Blake, William C. Dougall, John J. Miles, Michele W. L. Teng and Mark J. Smyth

1 Cancer Immunoregulation and Immunotherapy, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
2 Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
3 Human Immunity Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
4 Institute of Infection and Immunity, Cardiff University, Cardiff, UK.
5 School of Medicine, University of Queensland, Herston, Queensland, Australia.

*These authors contributed equally

Abstract

The receptors CD96 and TIGIT are expressed on the surface of T and NK cells and recent studies suggest both play important inhibitory roles in immune function. CD96 -/- has been shown to modulate immune cell activity in mice, with Cd96 mice displaying hypersensitive NK cell responses to immune challenge and significant tumor resistance. TIGIT overexpression has been shown to reduce NK cell-mediated cytotoxicity. TIGIT is also upregulated on T-cells during cancer and chronic viral infection, with expression associated with effector T-cell exhaustion and increased Treg suppression. The counterbalance between the putative inhibitory CD96, TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development. Blocking CD96 or TIGIT with monoclonal antibodies (mAbs) has been shown to improve tumor control in mice, in particular when used in combination with PD-1/PD-L1 blockade. These results have highlighted these pathways as promising new targets for immune modulation. This review will examine the rationale behind targeting CD96 and TIGIT and discuss the potential approaches in translating these preclinical findings into novel clinical agents.

Background

CD155, CD226 and TIGIT in immune regulation and cancer

The development of antibodies targeting immune checkpoint receptors PD-1 (1) and CTLA-4 (2) has been a monumental step forward in the clinical success of cancer immunotherapy. While highly successful as monotherapies, more than a dozen alternate pathways exist that modulate immune responses (3), suggesting combination approaches may greatly augment response rates. This hypothesis is supported by a recent clinical trial, demonstrating improved objective responses when PD-1 and CTLA-4 inhibitors were used in combination (4). While antibodies against CTLA-4 and PD-1 are thought to act predominately through T-cells, another immune cell type the natural killer (NK) cell is gaining traction as a target for cancer immunotherapy, particularly for the control of metastases and blood cancers (5). NK cells are part of the innate lymphocyte family and play a critical role in viral and tumor immune surveillance. NK cells act by detecting and killing infected or cancerous cells via perforin-mediated cytotoxicity and also regulate immune responses through the release of cytokines (6).

Candidate pathways for cancer immunotherapy include a cluster of immunoglobulin superfamily receptors that interact with nectin and nectin-like molecules (NECL), which are critical regulators in immune surveillance. Nectin and NECL family members were first characterized as adhesion...
molecules, mediating both homo- and heterophilic interactions (7). A diverse range of nectin and NECL proteins-receptor interactions exist, with roles in immune regulation, virus entry to cells and normal development (7, 8). Several nectin and NECL proteins have prominent roles in cancer surveillance, with CD155 (necl-5, PVR) the most well-characterized. While expression is low in normal tissue, CD155 is highly expressed on many cancer cell lines and primary tumors (9). CD155 has been linked with enhanced tumor proliferation (10) and migration (9). CD155 is also upregulated on many immune cells during inflammation (11) and on tumor-associated APCs (12). CD155 expression is thought to modulate T and NK cell responses through CD226, TIGIT and CD96 interactions (Table 1 and Figure 1).

Engagement between CD155 and CD226 or TIGIT has been a major focus of research, with CD226 having dual roles as both an activating and adhesion receptor on NK cells (13, 14), while TIGIT acts as an inhibitory receptor, shown to reduce NK cell cytokine production and cytotoxicity (15, 16). CD226 is also considered an activating receptor for CD8 T-cells (17) with its downregulation observed in advanced cancer and associated with T-cell exhaustion (12, 18). The role of CD226 in tumor immune surveillance is supported by accelerated tumor growth in Cd226 mice (19, 20). Conversely, TIGIT is highly upregulated on both CD8 T-cells and Tregs in many clinical tumor settings (12, 18, 21), with expression also correlating with other immune checkpoints such as PD-1. Across in vitro human assays, primate models and mouse tumor models, TIGIT blockade has been shown to enhance T-cell function in particular, in combination with other checkpoints such as PD-1(12), PD-L1 (21, 22) and TIM-3 (23). While CD155 is considered the dominant ligand for CD226 and TIGIT, CD226 can also interact with CD112 (24) and TIGIT can interact with CD112 and CD113 (25).

CD96 expression, ligand interactions and putative signaling pathways
CD96 (TACTILE) was first identified as an Ig superfamily receptor (26), however it is now known to be a member of the extended nectin/necl family and its role in immune function has received little attention until recently. CD96 expression is broadly similar between mice and humans, and is present on a proportion of hematopoietic stem cells, αβ and γδ T-cells, NK cells and a sub-population of B-cells in humans (27-31) and present on αβ and γδ T-cells, NK cells and NKT cells in mice (11, 32). CD96 is not expressed on other immune cells and expression is generally low or absent in organs without lymphocyte infiltrate (29). Of interest, CD96 is expressed at far higher levels in mice, with almost all cells positive for the receptor at resting state while basal expression is lower in humans (26). Interestingly, CD96 has been shown to be highly expressed in acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL) (29) and myelodysplastic syndromes (33). CD96 has additionally been proposed as a cancer stem cell marker in leukaemia (30, 33).

Akin to DNAM and TIGIT, the main ligand for CD96 is CD155, to which it binds with an affinity stronger than CD226, but weaker than TIGIT. Human CD96, CD226, TIGIT bind to CD155 with dissociation constants (Kd) of 37.6 nM, 119 nM and 3.15 nM respectively (25). Of note, mouse CD96 (mCD96) but not human CD96 (hCD96) has been shown to bind CD111 (nectin-1) (32). Other key differences also exist between human and mice. For example, hCD96 exists as two splice variants that confer different binding affinities to CD155 (29). The sequence of hCD96 but not mCD96 contains a potential SH-2 domain binding-site within the cytoplasmic tail in the form of an YXXM motif (29), similar to that found in activating receptors. Both human and mouse CD96 sequences contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs) (34) that putatively may provide inhibitory signals to lymphocytes following ligation. However, downstream signaling of the CD96 receptor has not been evaluated in detail. Given CD155 contains cytoplasmic signaling motifs, it will be of interest to determine whether CD96 engagement triggers reverse CD155 signaling. Indeed, TIGIT/CD155 ligation has been shown to modulate the function of CD155 expressing DC cells, inducing IL-10 secretion (25).
Functions of CD96

Initial investigations of CD96 biology suggested a role in mediating human NK cell adhesion to CD155 expressing target cells and was also proposed as a weak NK cell activating receptor (31). CD96 was also described as an adhesion molecule to CD155 and CD111 in mouse studies (29, 32). The first evidence that CD96 might be acting as an inhibitory receptor was shown in Cd96 mice, where NK cells produced greater IFN-γ responses to LPS, IL-12 or IL-18 stimulation (11). This study also demonstrated a role for CD96 in cancer immune surveillance, with Cd96 mice showing robust resistance to experimental lung metastases and MCA-induced fibrosarcomas. The potential of targeting CD96 to enhance NK cell control of metastases was highlighted in our recent article (35). In this study, we demonstrated that mAbs against CD96 could reduce the number of lung metastases in a range of spontaneous and experimental models. The activity of anti-CD96 was dependent on NK cells, IFN-γ and CD226.

Clinical-Translational Advances

Therapeutic approaches

The complexity of interaction dynamics within the CD96/TIGIT/CD226/CD155 axis poses both opportunities and challenges for therapeutic translation in oncology. At the most fundamental level, the net inhibitory signals from either TIGIT or CD96 are counterbalanced via multiple mechanisms by the activating signal of CD226. Thus, an understanding of the dynamic regulation of CD226 expression and activity must be a core consideration when attempting to modulate TIGIT and CD96 activity. Therapeutic antibodies that reduce co-inhibitory signaling via blockade of CD155 binding to CD96 and/or TIGIT have considerable experimental support in preclinical cancer models (21, 35). These data support a correlation between antibody blockade of the CD96/TIGIT/CD155 axis with enhanced anti-cancer activity through increased +CD8 T-cell or increased NK cell function for anti-TIGIT and anti-CD96, respectively. As an alternative to blockade of ligand binding to co-inhibitory receptors, antibodies that stabilize CD155 binding to CD226 might selectively potentiate an activating signal, and may serve as a therapeutic strategy by providing a more robust counterbalance to TIGIT and CD96.

Functional TIGIT suppression of anti-tumor responses is both intrinsic to effector T-cells and indirect, via enhancement of Treg activity. The enrichment of TIGIT expression on tumor-infiltrating Tregs compared to peripheral Tregs (23) would suggest that maximal anti-tumor response could be achieved via modification of the mAb Fc region. Increased binding to activating FcR could mediate a selective +depletion of TIGIT Tregs at the tumor site through antibody dependent cellular-cytotoxicity (ADCC) or -phagocytosis (ADCP), similar to what has been described for anti-CTLA-4 antibodies (36). The relatively greater TIGIT expression on Tregs versus T-effector cells within tumor site would optimally enable this approach. While +CD96 is expressed on CD4 T-cells (11), further work is necessary to determine whether CD96 influences the suppressive function of Tregs, and to define CD96 expression on Tregs and Teff within the tumor microenvironment and periphery. Importantly, the ability of blocking CD96 mAb to reduce B16F10 lung metastases was not dependent on activating FcR (35), indicating that anti-tumor activity was not due to selective immune subset depletion.

Since receptor-binding domains are conserved in CD155 (25), therapeutic antibodies targeting this ligand are not likely to have selective effects on inhibitory (TIGIT and CD96) signals versus activating (CD226) pathways. However, the relatively higher binding affinity of CD155 to TIGIT or CD96 compared with the lower affinity CD226 interaction can theoretically be exploited for drug development. Greater selectivity towards CD226-dependent signaling and subsequent lymphocyte activation could be achieved using engineered variants (or “muteins”) of CD155 or other nectins that retain TIGIT and/or CD96 binding but cannot bind CD226. By competing with native CD155, these...
modalities would functionally block TIGIT and/or CD96 inhibitory signaling but retain the activation through CD226. The ability of TIGIT to form a signaling-competent homodimer (37) or, conversely, a heterocomplex with CD226 which impairs CD226 activation signaling (21), reveals the dynamic interactions of this receptor system and other potential anti-cancer drug approaches. Antibodies that target the interface between TIGIT homodimers may reduce inhibitory signaling, while targeting interactions between TIGIT and CD226 extracellular domains might conceivably block heterocomplex formation and relieve TIGIT-mediated inhibition of CD226 signaling.

Preclinical mechanistic data and known lymphocyte expression patterns suggests that combination immunotherapy strategies targeting TIGIT and/or CD96 will have improved anti-tumor responses. For instance, combining anti-CD96 with either anti-CTLA-4 or anti-PD-1 mAbs resulted in a greater reduction in B16F10 lung metastasis compared to monotherapy treatment, an effect dependent on NK cells (35). Moreover, survival of mice with 4T1.2 spontaneous metastases, was significantly increased by combining anti-CD96 and anti-CTLA-4 or anti-PD-1 compared to monotherapy. Similarly, treatment of CT26 tumors with a combination of anti-TIGIT and anti-PD-L1 dramatically improved anti-tumor responses compared to each as a monotherapy -/- (21), while using an anti-TIM-3 mAb in Tigit mice improved the control of B16F10 metastases and subcutaneous tumors (23). There is also evidence that targeting TIGIT -/- and CD96 in combination could be exploited as a therapeutic strategy. While Tigit mice showed enhanced immunity to either B16F10 melanoma grown as subcutaneous -/-tumors (23), experimental B16F10 lung metastasis were not reduced in Tigit mice -/- (11). However treatment of Tigit mice with an anti-CD96 mAb resulted in a greater reduction of B16F10 or EO771 lung metastasis than that observed upon anti-CD96 mAb treatment in wild-type mice (35), suggesting that these pathways may instruct non-overlapping lymphocyte subsets and/or distinct molecular mechanisms.

While immunotherapy functions by increasing host anti-tumor immunity, the induction of immune-related adverse events (irAEs) in patients can limit certain approaches. Clinically, CTLA-4 blockade is associated with more high-grade irAEs -/- than PD-1 (4), and in agreement, Ctlal-4 mice develop a lethal lymphoproliferative -/-disorder (38). However, Pd-al mice, can spontaneously develop a range of less -/- -/-severe immune pathologies (39, 40). To date, Tigit (41) or Cd96 mice (11) have -/- -/- not shown spontaneous development of overt immune pathologies, however Tigit mice were more sensitive to the induction of experimental autoimmune encephalomyelitis (41) and TIGIT blockade was shown to increase experimental arthritis development (42). While caution in the over interpretation of animal studies is advised, these preclinical observations suggest CD96 or TIGIT blocking therapies may have favourable clinical toxicity profiles.

Open questions and challenges
Currently, the foremost challenge for translating TIGIT- or CD96-targeted therapies is to functionally validate blockade of these receptors in human lymphocytes. Two useful validation surrogates include the analysis of TIGIT and CD96 expression/function in patient tumor infiltrating lymphocytes (TILs), or on T-cells from chronic virus-infected individuals, and any correlation with exhaustion markers +and/or phenotype. TIGIT was reportedly co-expressed with PD-1 on effector CD8 T-cells during HIV or SIV infection and increased TIGIT expression correlated with + +disease progression (22). TIGIT levels were elevated on CD4 and CD8 TILs and co-expressed with PD-1 on CD8 T-cells in NSCLC, colon cancer and melanoma samples (12, 21), with similar expression seen on PBMCs from AML patients (18). + Promisingly, treatment of HIV-specific CD8 T-cells with an anti-TIGIT mAb increased IFN-γ production (22). Similarly, treatment of tumor-specific melanoma +CD8 TILs with anti-TIGIT mAb augmented proliferation and IFN-γ production (12, 43). These data are consistent with a co-inhibitory function for TIGIT in the context of chronic antigen stimulation in humans and provide a sound rationale for further development of TIGIT blockade therapeutics.
Currently, the validation of hCD96 as a potential immunotherapy target is not as advanced as TIGIT. While CD96 surface expression is increased on human T-cells post activation (26, 44), a high percentage of resting CDB T-cells from healthy + controls express CD96 and the fraction of CD96 CD8 T-cells was reduced in HIV-infected individuals (44). Interestingly, serum levels of soluble CD96 were found to be elevated in patients with chronic viral hepatitis B infection (45), suggesting that persistent antigen exposure can increase CD96 levels and/or cell surface shedding. In human cancers, CD96 surface expression on TILs versus PBMCs has not been well characterized, however CD96 mRNA expression, along with TIGIT, was highly expressed and associated with a T-cell signature in lung cancer (21). Current data from preclinical cancer models indicates an inhibitory function for CD96 on NK cells, but whether the same function exists on mouse T-cells and human NK or T-cells remains to be elucidated. The determination of CD96 expression in human T-cell subsets, TILs and a comprehensive validation of functional pathway activity in human immune cells is an area of active research and are obligatory prerequisites for the development of CD96 blockade therapeutics.

Presently, the relationship between specific structural/biophysical attributes and optimal anti-cancer mechanisms of TIGIT- or CD96-targeted therapies are not well described. The rationale for blocking CD155/TIGIT binding to augment CD8 T-cell function as a cancer immunotherapy approach is sound. While TIGIT robustly inhibits human NK cell-mediated cytotoxicity in vitro (16, 46), in mice, TIGIT NK cell-mediated tumor suppression is less pronounced than CD96 (11). Moreover, the high potentially dominant contribution of TIGIT Treg cells in the anti-cancer immune response (23) suggests that a blocking antibody might also augment effector functions. These observations should be reconciled to understand the full, integrated contribution of TIGIT on distinct lymphocytes (eg CD8 T-cells, CD4 T-cells and NK cells) for an optimal anti-tumor response.

The ability of CD96 or TIGIT to counterbalance activation mediated by CD226 appears to drive most of the anti-cancer activities of CD96/TIGIT targeted therapies. Indeed, a CD226 blocking antibody reversed suppression of CT26 tumors by an anti-TIGIT mAb (21). Similarly, CD96 suppression of B16F10 lung metastases, via genetic deletion or blocking antibody was mostly dependent on intact CD226 function (11, 35). Within this paired inhibitory/activating axis, the magnitude and integrated quality (activation versus inhibition) of lymphocyte signaling is dictated by the relative availability (and selective competitive binding) of certain ligands but also by the kinetics and coordinated expression of receptor levels. To this end, CD226 was down regulated on CD8 T-cells and NK cells in AML patients (18, 47), and low CD226 was detected on CD8 TILs from melanoma patients compared with PBMCs (12). CD226, TIGIT and CD96 receptor expression was reportedly dynamically modulated by ligand exposure. CD155 interaction decreases surface expression of CD226 (48) and CD96 (31) on contacting cells. Conversely, increased levels of -/-CD226 and CD96 have been observed in Cd155 mice, while TIGIT levels were unchanged (49). These dynamic alterations in activating and inhibitory receptor levels may tip the balance in net signaling output in a context-dependent manner and potentially alter responses to CD96- and TIGIT- targetted therapies.

Clearly, emerging preclinical evidence suggests there is much promise in modulating the CD96/TIGIT/DNAM/CD155 axis for immuno-oncology. A clearer understanding of the molecular- and context-dependent mechanisms by which CD96 and TIGIT 13 function in immunity will pave the way for its therapeutic application in cancer, either as monotherapies or in combination with other therapies. At this stage, the ultimate impact of fine-tuning the function of TIGIT and CD96 receptors on cancer patient outcomes are wholly unknown but will be interesting to monitor as knowledge advances.

References


Table 1. Biological roles of TIGIT and CD96 in lymphocyte function and outcomes of pathway inhibition relevant to immunotherapy

<table>
<thead>
<tr>
<th></th>
<th>TIGIT</th>
<th>CD96</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>T-cells</strong></td>
<td>• Increased T-effector cell function in <em>tigir</em>−/− knockout or anti-TIGIT mAb treated mice, increased human T-effector function following antibody treatment or shRNA knockdown <strong>REFS (12, 21, 22, 41, 50)</strong></td>
<td>• Role of CD96 in T-cell function currently unknown</td>
</tr>
<tr>
<td></td>
<td>• Reduced suppressive function of Treg cells; reduced suppression of anti-tumor immune responses by <em>tigir</em>−/− Tregs, increased suppression of Th1, Th17 immune responses by TIGIT compared to TIGIT−/− Tregs in mice <strong>REFS (23, 51)</strong></td>
<td>• Surface expression of CD96 upregulated on activated human T-cells <strong>REF (26)</strong></td>
</tr>
<tr>
<td></td>
<td>• Associated with markers of T-cell exhaustion in tumors or chronic viral infections, blockade improves effector T-cell function <strong>REFS (12, 18, 21, 22, 43)</strong></td>
<td>• CD96 mRNA expression increased and associated with a T-cell signature in non-squamous non-small cell lung cancer cohort <strong>REF (21)</strong></td>
</tr>
</tbody>
</table>

| **NK cells**   | • Blockade of TIGIT-CD112/CD155 interactions increases human and mouse NK cell cytotoxicity and IFNγ production **REFS (15, 16, 46)** | • Putative adhesion molecule of mouse and human NK cells **REFS (29, 31, 32)** |
|                | • *Tigir*−/− mice do not have increased protection from lung metastases **REFS (11, 35)** | • Putative activating receptor for human NK cells **REF (31)** |

Figure 1. The regulation of inhibitory versus activation signals in NK cell and T-cells by CD96/TIGIT/CD226 receptors is achieved by complex receptor/ligand and receptor/receptor counterbalancing mechanisms. CD155 and CD96, TIGIT, CD226 are all members of the Ig superfamily and all share similar variable or constant Ig motifs in the extracellular domains, single-pass transmembrane regions and short cytoplasmic domains.

A). CD155 levels on different cells are upregulated as a result of cellular stress. In cancer, CD155 is increased on transformed cells and antigen presenting cells (APC) within the tumor microenvironment and is sensed by the CD96/TIGIT/CD226 receptors to modulate anti-tumor immunity.

B). Upon exposure to increasing levels of CD155, the net activation or inhibition of lymphocytes is fine-tuned by the integrated signalling of CD96, TIGIT and CD226. This net integration is dictated by the relative binding affinity of CD155 for different receptors, relative abundance of activation
(CD226) vs. inhibitory (CD96, TIGIT) receptors, the strength and quality of signal transduction by each receptor and the modulation of ligand binding and biochemical signal transduction by homo- and heterodimerization of receptor complexes. The cytoplasmic domain of CD226 has a tyrosine (Y322) and serine (S329), which become phosphorylated in a CD155-dependent manner. Phosphorylation of Y322 confers binding of CD226 to the SH2-domain containing protein Grb2 and downstream signalling. Serine 329 phosphorylation of CD226 mediates activation of protein kinase C and the association with lymphocyte function-associated antigen 1 (LFA1) as an intermediate for further signal transduction. TIGIT contains an immunoreceptor tyrosine inhibitory motif (ITIM) domain and an immunoglobulin tail tyrosine (ITT) motif within the cytoplasmic tail. Upon ligand binding, both the ITT and ITIM domains of TIGIT are phosphorylated and recruit adaptor and signaling molecules. While both mCD96 and hCD96 contain an ITIM-like domain, the human CD96 cytoplasmic domain uniquely also includes a YXXM motif. A detailed review of CD226, TIGIT and CD96 signaling mechanisms is described in (8).

C). These molecular regulatory mechanisms provide distinct opportunities for drug development in immuno-oncology. 1). Therapeutic antibodies that block CD155 binding to CD96 or TIGIT would reverse the inhibitory signaling by these receptors. Using either anti-CD96 or anti-TIGIT mAbs, this approach has received specific experimental support in mouse cancer models. 2). Antibody or mutated ligand ("mutein") modalities which allow preferential signaling through the activating receptor CD226 might tip the balance between CD155-dependent activation and inhibition. For instance, a mAb that recognizes and stabilizes the unique interaction complex of CD155/CD226 could enhance stimulatory signaling through CD226. Alternatively, engineered mutations in CD155 muteins that preferentially bind CD96 and/or TIGIT might competitively inhibit native CD155 binding and enhance lymphocyte activation. 3). The blockade of TIGIT/CD226 heterodimer or TIGIT/TIGIT homodimer by drug modalities would potentially reduce TIGIT-dependent inhibitory signals.

Figure 1: